Niche Biopharmaceuticals is developing NB2, a topical small‑molecule therapeutic that combines direct antimicrobial activity with built‑in anti‑inflammatory effects in a single new chemical entity. The drug shows broad‑spectrum potency against over 40 bacterial strains and enveloped viruses, and pre‑IND work is underway for atopic dermatitis and diabetic foot ulcer indications, with no resistance observed after 52 weeks of continuous exposure.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with atopic dermatitis and diabetic foot ulcers often suffer from chronic skin infections that are difficult to treat due to bacterial resistance and concurrent inflammation, leading to prolonged healing times and increased risk of complications.
Solution
Niche Biopharmaceuticals is developing NB2, a topical small‑molecule new chemical entity that combines direct antimicrobial activity with intrinsic anti‑inflammatory effects in a single compound. The drug exhibits microgram‑per‑milliliter potency against more than 40 bacterial strains, including Staphylococcus aureus implicated in atopic dermatitis, as well as activity against enveloped viruses such as SARS‑CoV‑2. NB2’s chemical class (CAIT) is designed to be resistance‑resilient, showing no resistance development after 52 weeks of continuous exposure at sub‑minimum bactericidal concentrations. The molecule is lipase‑resistant, ensuring stability on the skin, and is being advanced toward first‑in‑human trials for the two lead indications.
Target Audience
Primary customers are dermatology and wound‑care clinicians treating atopic dermatitis and diabetic foot ulcer patients, as well as pharmaceutical partners seeking a novel topical therapy with combined anti‑infective and anti‑inflammatory properties.
Features
- Broad-spectrum antimicrobial activity (µg/mL) against >40 bacterial organisms and enveloped viruses
- Built‑in anti‑inflammatory mechanism, providing dual therapeutic action without a combination product
- Resistance‑resilient profile demonstrated by 52 weeks of continuous exposure without resistance emergence
- Lipase‑resistant formulation derived from glycerol monolaurate, enhancing topical stability
- Classified as a new chemical entity, qualifying for 5‑year FDA exclusivity upon approval
- Pre‑IND meeting completed for the atopic dermatitis program; DFU IND planning underway